1Creusot RJ, Fathman CG. Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity. J Clin Invest,2004,114 : 892-894.
2Furlan R, Butti E, Pluchino S, et al. Gene therapy for autoimmune diseases. Curr Opin Mol Ther,2004,6:525-536.
3Cope AP, Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol,2004,16:780-786.
4Ho SH, Hahn W, Lee HJ, et al. Protection against collagen-induced arthritis by electrotransfer of an expression plasmid for the interleukin-4. Biochem Biophys Res Commun ,2004,321:759-766.
5Kim SH, Lechman ER, Bianco N, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol,2005,174:6440-6448.
6Howard LM, Miller SD. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.Autoimmunity ,2004,37:411-418.
7Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev,2005 ,57 :187-215.
9Takahashi H, Kato K, Miyake K, et al. Adeno-associated virus vector-mediated anti-angiogenie gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol,2005,23:455-461.
10Chen Y, Donnelly E, Kobayashi H, et al. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum,2005,52 : 1346-1348.
3Sambrook J, Fritsch EF, Maniatis T,et al. Molecular Cloning: a laboratory manual. 2nd ed. New York: cold Spring Harbor Laboratory Press,1989.1847-18586.
4Horton RM, Hunt HD, Ho SN, et al. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.Gene,1989,77:61-68.
5Wu JJ,Li WJ,Lei HX,et al.Goldkey:a software system for sequence analysis of nucleic acid and protein.Newsletter Biotechnol,1994, 5:189-193.
6Kawooya JK, Treat JC, Kirschner RJ, et al. The expression, affinity purification and characterization of recombinant Pseudononas exotoxin 40 (PE40) secreted from Escherichia coli. J Biotech, 1995, 42: 9-22.
7Kleber-Janke T, Becker WM. Use of modified BL21(DE3) Escherichia coli cells for high-level expression of recombinant peanut allergens affected by poor codon usage. Protein Expr Purif,2000,19:419-424.
8Kreitman RJ.Immunotoxin in cancer therapy.Curr Opin Immunol,1999,570-578.
9Debinski W, Pastan I. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Res, 1992, 2: 5379-5385.
10Tazzari PL, Polito L, Bolognesi A,et al. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model. J Immunol ,2001,167:4222-4229.
